Meeting
2021 Gastrointestinal Cancers Symposium
Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms.
Authors
Taymeyah E. Al-Toubah
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Taymeyah E. Al-Toubah , Jennifer Gile , Jonathan R. Strosberg , Thorvardur Ragnar Halfdanarson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Neuroendocrine/Carcinoid
Track
Neuroendocrine/Carcinoid
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 370)
DOI
10.1200/JCO.2021.39.3_suppl.370
Abstract #
370
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Outcomes of combined ipilimumab/nivolumab in metastatic uveal melanoma: A prevalence meta-analysis.
First Author: Ceren Durer
Poster
2020 ASCO Virtual Scientific Program
Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.
First Author: Bradley Alexander McGregor
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of oral chemotherapy with capecitabine and temozolomide (CapTem) in metastatic neuroendocrine tumors (NETs): A single-institution experience.
First Author: Valeria Smiroldo
Poster
2024 ASCO Annual Meeting
Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon